Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance

20260 citationsJournal Article

Authors

Hardik Chandasana · Simulation Technologies (United States)

Ann M. Buchanan · ViiV Healthcare (Spain)

Cassidy Henegar · ViiV Healthcare (Spain)

Michael J. McKenna · Health and Safety Executive

Cindy Vavro · ViiV Healthcare (Spain)

Ana Cristina Puga · ViiV Healthcare (Spain)

Cindy Brothers ·

Abstract

Twice-daily dosing of Dolutegravir is approved for adults with HIV and integrase strand transfer inhibitor resistance, but not for children. Population pharmacokinetic modeling and simulations identified a weight-tiered twice-daily dose for children, predicted to yield dolutegravir exposures within the therapeutic window and provide similar efficacy and safety as seen in adults with HIV-1 and first-generation integrase strand transfer inhibitor resistance.

Topics & Keywords

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions HIV-related health complications and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Pediatric Infectious Disease Journal

DOI: 10.1097/inf.0000000000005158

Field-Weighted Citation Impact: 0.00